36.06
Royalty Pharma Plc (RPRX) 재무 분석
손익 계산서
분기별
*모든 숫자는 백만 단위입니다.
기간 종료일 | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
기간 | 3개월 | 3개월 | 3개월 | 3개월 | 3개월 |
Revenues |
1.83%
578.66
|
568.25 | 564.69 | 537.27 | 567.98 |
|
982.83%
368.87
|
34.06 | -170.38 | 267.64 | 641.75 |
Benefits Costs and Expenses |
262.00%
488.03
|
134.81 | -241.67 | 342.89 | 572.25 |
Costs And Expenses |
982.83%
368.87
|
34.06 | -170.38 | 267.64 | 641.75 |
Provision For Loan, Lease, And Other Losses |
41.43%
7.911
|
13.51 | -33.72 | -30.90 | 0.669 |
Operating Income/Loss |
60.73%
209.80
|
534.18 | 735.07 | 269.63 | -73.77 |
Nonoperating Income/Loss |
18.28%
-119.16
|
-100.75 | 71.28 | -75.25 | 69.50 |
Income/Loss Before Equity Method Investments |
79.40%
87.94
|
426.99 | 795.95 | 192.67 | 9.876 |
Income/Loss From Equity Method Investments |
58.20%
2.693
|
6.443 | 10.41 | 1.703 | -14.15 |
Income/Loss From Continuing Operations Before Tax |
79.09%
90.64
|
433.43 | 806.36 | 194.38 | -4.273 |
Income Tax Expense/Benefit |
-
|
- | - | - | - |
Income/Loss From Continuing Operations After Tax |
79.09%
90.64
|
433.43 | 806.36 | 194.38 | -4.273 |
|
79.09%
90.64
|
433.43 | 806.36 | 194.38 | -4.273 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
69.01%
60.46
|
195.08 | 262.37 | 92.37 | -9.051 |
Basic Average Shares |
2.75%
423.51
|
435.48 | 447.63 | 451.02 | 448.62 |
Diluted Average Shares |
2.73%
562.30
|
578.10 | 592.73 | 596.91 | 597.48 |
Basic Earnings Per Share |
87.27%
0.07
|
0.55 | 1.22 | 0.23 | 0.01 |
Diluted Earnings Per Share |
87.27%
0.07
|
0.55 | 1.21 | 0.23 | 0.01 |
Common Stock Dividends |
0.00%
0.22
|
0.22 | 0.21 | 0.21 | 0.21 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
자본화:
|
볼륨(24시간):